OMERS ADMINISTRATION Corp Makes New Investment in Hims & Hers Health, Inc. $HIMS

OMERS ADMINISTRATION Corp purchased a new position in Hims & Hers Health, Inc. (NYSE:HIMS) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 19,200 shares of the company’s stock, valued at approximately $399,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Binnacle Investments Inc purchased a new stake in shares of Hims & Hers Health during the third quarter valued at $28,000. Silicon Valley Capital Partners bought a new stake in Hims & Hers Health in the 3rd quarter worth about $48,000. Flagship Harbor Advisors LLC purchased a new position in Hims & Hers Health in the 4th quarter worth about $28,000. Bogart Wealth LLC raised its position in Hims & Hers Health by 235.8% in the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after buying an additional 632 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its stake in Hims & Hers Health by 273.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock valued at $47,000 after acquiring an additional 687 shares during the period. 63.52% of the stock is owned by institutional investors.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: One bullish analysis argues that Hims & Hers remains undervalued, citing projected revenue growth, approximately 73% gross margins, accelerating subscriber additions, GLP-1 and peptide demand, international expansion, and the Novo Nordisk partnership. The thesis suggests substantial long-term upside if the company sustains growth despite the regulatory controversy. Hims & Hers Health: Still an Undervalued Company With Tremendous Upside
• Neutral Sentiment: Several law firms, including SBS Law, Kaplan Fox, Howard G. Smith, and Holzer & Holzer, announced investigations into possible securities-law violations. These announcements are typically investor-solicitation notices and do not establish wrongdoing, but they raise the possibility of shareholder litigation and additional disclosure obligations. SBS Law Investigation
• Negative Sentiment: The FTC alleges Hims & Hers shared customers’ health information with advertising platforms including Meta and Snap, failed to clearly disclose prescription charges, and used potentially deceptive billing and privacy practices. The lawsuit could lead to penalties, higher compliance expenses, tighter restrictions on marketing, and damage to consumer trust. Media coverage of the action contributed to a sharp decline in the shares and remains the principal near-term risk for HIMS. FTC Sues Hims & Hers

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $27.79 on Friday. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $70.43. The firm has a market capitalization of $6.43 billion, a price-to-earnings ratio of -308.74, a price-to-earnings-growth ratio of 76.10 and a beta of 2.35. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18. The firm has a 50 day moving average of $31.23 and a 200 day moving average of $26.12.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.44). The business had revenue of $608.10 million during the quarter, compared to the consensus estimate of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The firm’s revenue was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.20 earnings per share. On average, research analysts anticipate that Hims & Hers Health, Inc. will post 0.03 earnings per share for the current year.

Insider Transactions at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock in a transaction on Monday, July 6th. The stock was sold at an average price of $36.49, for a total transaction of $261,377.87. Following the transaction, the chief financial officer directly owned 284,321 shares in the company, valued at approximately $10,374,873.29. The trade was a 2.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Patrick Harrison Carroll sold 23,726 shares of the business’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $35.00, for a total value of $830,410.00. Following the sale, the insider directly owned 181,861 shares of the company’s stock, valued at $6,365,135. This represents a 11.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 83,126 shares of company stock worth $2,711,339 over the last three months. 11.76% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on HIMS shares. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. Truist Financial boosted their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Friday, July 24th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $25.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, May 5th. Canaccord Genuity Group raised their target price on shares of Hims & Hers Health from $32.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. Finally, Weiss Ratings downgraded shares of Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research report on Tuesday, May 12th. Four analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Hims & Hers Health has an average rating of “Hold” and an average target price of $31.43.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.